ALK and non-small cell lung carcinoma: With a minimum of 15.7-month follow-up, neoadjuvant immunochemotherapy reduced the risk of death or progression by 42% while pCR has been significantly improved to 25.3% compared with 4.7% by chemotherapy.16 Ever since then neoadjuvant nivolumab plus chemotherapy has become the most promising neoadjuvant treatment option for resectable NSCLC without EGFR/ALK alternations.